Medicine

New Framework Could Transform How We Prevent and Detect Cancer

How the science connects

Personalized medic…Cancer screeningCancer prevention

AI Insight

This article presents a precision prevention and early detection (PPED) framework for cancer control that personalizes interventions based on individual risk profiles. Currently, only 13% of cancers are detected through guideline-based screening, and 20-50% are first diagnosed in emergency departments, despite stage at diagnosis being the strongest predictor of survival. The PPED approach addresses who is at elevated risk, what preventive interventions are appropriate, when and at what intensity they should be applied, and how and where services should be delivered, emphasizing both escalation of care for high-risk individuals and de-escalation for low-risk populations.


This framework could significantly improve cancer outcomes by shifting detection to earlier, more treatable stages through risk-stratified screening approaches. It has potential to reduce healthcare costs and patient burden by avoiding unnecessary interventions in low-risk individuals while intensifying prevention efforts for those at higher risk.


Understand the Science

Personalized medicine 14 articles Explore Concept → Cancer screening Concept coming soon Cancer prevention Concept coming soon

Stage at diagnosis remains the strongest determinant of cancer survival, yet only 13% of cancers are detected through guideline-based screening, and 20–50% first present in an emergency department. Precision prevention and early detection (PPED) tailors cancer control by asking who is at elevated risk of developing cancer, what preventive intervention is appropriate, when should intervention be applied and at what intensity, and how and where preventive services should be delivered. De-escalation of preventive interventions in low-risk individuals is as important as preventive care escalation in high-risk individuals.

Source: [Lecture] Precision prevention and early detection: framework for a new clinical cancer control pathway